ASHM Report Back

Clinical posts from members and guests of the Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine (ASHM) from various international medical and scientific conferences on HIV, AIDS, viral hepatitis, and sexual health.

Changes to PEP recommendations

  • Font size: Larger Smaller
  • Hits: 1355
  • Print

Quick update on a presentation by John McAllister

 

  • if source VL is undetectable, then PEP is no longer recommended
    • however, do need to discuss the reliability of the history of undetectable VL
  • Truvada should be used for PEP
    • avoid tenofovir and lamivudine (although cheaper)
  • 3-drug PEP
    • if 3 drugs are needed, then stick with dolutegravir (ALT increases by 22%), raltegravir or rilpiravine

 

  • No comments made yet. Be the first to submit a comment

Leave your comment

Guest
Guest Monday, 26 July 2021
Twitter response: "To protect our users from spam and other malicious activity, this account is temporarily locked. Please log in to https://twitter.com to unlock your account."